Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ciba “square-round-edge” IOL

This article was originally published in The Gray Sheet

Executive Summary

Ciba is building inventory for a planned late-2002 U.S. launch of its CV232 square-round-edge intraocular (IOL) lens following supplemental PMA approval, announced May 31. The design combines a square posterior edge, to facilitate 360-degree capsular contact, and a rounded anterior edge, to reduce glare. While Ciba believes the square posterior edge "may improve postoperative results," FDA has not approved a specific claim related to this potential advantage, and has issued warning letters to IOL manufactures claiming a square edge reduces posterior capsule opacification (1"The Gray Sheet" Oct. 8, 2001, p. 10)...

You may also be interested in...

FDA Struggles To Contain IOL Competitive Claims, Issues Pharmacia Warning

Pharmacia is the third intraocular lens company in the last three years to be cited by FDA for improper marketing claims related to posterior capsule opacification (PCO).

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts